Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder (SCORPIO)
This study has been completed.
Study NCT00689104   Information provided by Astellas Pharma Inc
First Received: May 29, 2008   Last Updated: April 16, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Urinary Bladder, Overactive
More general conditions related to this trial
Signs and Symptoms
Urinary Bladder Diseases
Urologic Diseases
Urological Manifestations
Interventions listed in this trial
YM178
Tolterodine 4 mg
Placebo
Additional drug interventions recognized in this trial
Tolterodine
More general drug interventions related to this trial
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Astellas Pharma Inc


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services